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Background: We used cardiovascular magnetic resonance (CMR) to investigate the association between epicardial
adipose tissue (EAT) thickness and silent myocardial ischemia, as well as coronary artery stenosis, in asymptomatic
type 2 diabetic patients.
Methods: The study included 100 type 2 diabetic subjects (51 male and 49 female; mean age: 56 ± 7 years). Silent
myocardial ischemia, as determined by CMR, was defined as evidence of inducible ischemia or myocardial
infarction. Signal reduction or stenosis of≥ 50% in the vessel diameter was used as the criteria for significant
coronary artery stenosis on coronary magnetic resonance (MR) angiography.
Results: EAT thickness was positively correlated with body mass index (BMI), waist-to-hip ratio, systolic blood
pressure, postprandial glucose, fasting/postprandial triglyceride (TG), serum glycated hemoglobin (HbA1c) level, and
homeostasis model assessment of insulin resistance (HOMA-IR) score. Significant coronary artery stenosis was found
in 24 patients, while 14 patients had silent myocardial ischemia in CMR (1 with silent myocardial infarction, 11 with
inducible ischemia, and 2 with both). EAT thickness was greater in patients who had coronary artery stenosis
(13.0 ± 2.6 mm vs. 11.5 ± 2.1 mm, p= 0.01), but did not differ between the subjects with or without silent myocardial
ischemia on CMR images (12.8 ± 2.1 vs. 11.7 ± 2.3 mm, p= 0.11). Multivariate logistic regression analysis indicated
that EAT thickness was an independent indicator for significant coronary artery stenosis after adjusting for
traditional risk factors (OR 1.403, p= 0.026).
Conclusions: Increased EAT thickness assessed by CMR is an independent risk factor for significant coronary
artery stenosis in asymptomatic type 2 diabetes. However, EAT thickness was not associated with silent
myocardial ischemia.
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Epicardial adipose tissue (EAT) is a metabolically active
visceral fat deposit found around the heart, between the
pericardium and myocardium [1]. Transthoracic echo-
cardiography (TTE) and multi-slice computed tomog-
raphy (MSCT) scanning have been conventional
methods for quantifying EAT [2]. Growing evidence sug-
gests that EAT has clinical relevance in that it produces
several proatherogenic molecules and influences the de-
velopment and progression of coronary artery disease
(CAD) [1,3,4]. Bettencourt et al. showed that EAT vol-
ume assessed by MSCT is positively and independently
related to coronary atherosclerotic burden [5]. Similarly,
Harada et al. reported that EAT volume is significantly
increased in patients with acute coronary syndrome [6].
However, EAT images do not provide information on
the functional status of myocardial cells such as viability,
ischemia, and infarction.
Over the past several years, cardiac magnetic reson-
ance (CMR) has been increasingly used for the assess-
ment of patients with ischemic heart disease [7]. CMR
offers a functional analysis of myocardial first-pass per-
fusion and delayed gadolinium enhancement for detec-
tion of myocardial infarction, as well as luminal
assessment of the coronary artery. Recently, several trials
have evaluated the association between epicardial or
pericardial fat assessed by CMR and vascular function
[8] or inflammatory markers [9] in subjects with obesity
and metabolic syndrome. In the present study, we evalu-
ated patients with diabetes mellitus, another important
risk factor for CAD [10]. Specifically, we used CMR to
assess the association between EAT thickness and myo-
cardial ischemia, as well as coronary artery stenosis, in
asymptomatic type 2 diabetic patients.
Methods
Subjects
The study included 100 Korean asymptomatic diabetic
patients who were enrolled in a prospective trial that
evaluated the role of endothelial progenitor cell count in
CAD [11]. Study methods were described in detail in
previous reports. None of the participants had a history
of cardiovascular disease (angina, myocardial infarction
(MI), cerebrovascular diseases (CVD), or peripheral ar-
tery disease (PAD)), malignancy, or severe renal or hep-
atic disease. They answered the Rose questionnaire [12]
and reported no chest pain or equivalent symptoms. The
Institutional Review Board of Yonsei University College
of Medicine approved this study, and all subjects pro-
vided informed consent in accordance with the ethical
committee and the Korean Good Clinical Practice
guidelines.
The patients’ records were reviewed to verify the dur-
ation of diabetes. The body mass index (BMI) wascalculated as weight divided the square of height (kg/m2),
and waist circumference was measured at the midpoint
between the lateral iliac crest and the lowest rib. Hip cir-
cumference was measured at the maximal protrusion of
the greater trochanter, and waist-to-hip ratio (WHR) was
calculated as the ratio of waist-to-hip circumference.
Blood pressure was measured twice with a mercury sphyg-
momanometer on the right upper arm after resting for at
least 10 minutes in sitting position, taking the average
values of systolic and diastolic blood pressures. Metabolic
syndrome was defined according to criteria of the Adult
Treatment Panel III (ATP III) of the National Cholesterol
Education Program (NCEP’s). The modified ATP III defin-
ition of metabolic syndrome requires the presence of at
least three or more of the following five components: 1)
elevated waist circumference ≥ 90 cm (male), ≥ 80 cm
(female); 2) elevated triglyceride (TG)> 150 mg/dL
(1.695 mmol/L); 3) reduced high-density lipoprotein
(HDL) cholesterol< 40 mg/dL (male), < 50 mg/dL
(female); 4) hypertension or elevated blood pressure ≥
130/85 mm Hg; or 5) diabetes or elevated fasting plasma
glucose ≥ 5.6 mmol/L [13].
Laboratory methods were described in detail in previ-
ous reports [11]. Briefly, all blood samples were obtained
in the morning after a 12-hour overnight fast, and we
performed a standardized mixed meal stimulation test in
all subjects using commercial liquid nutritional supple-
ments (Ensure, Meiji Dairies Corporation, Tokyo, Japan;
total 500 kcal, 17.5 g fat, 68.5 g carbohydrate, and 17.5 g
protein) [14]. Blood samples were collected at 0 and
90 min after taking the liquid supplement (basal and sti-
mulated levels, respectively) for glucose, TG, insulin, and
C-peptide analyses. Plasma glucose was measured using
the glucose oxidase method. Plasma TG, total choles-
terol, HDL- cholesterol, blood urea nitrogen, creatinine,
AST, and ALT levels were assayed using a routine Hita-
chi 7600 autoanalyzer (Hitachi Instruments Service,
Tokyo, Japan). Low-density lipoprotein cholesterol
(LDL- cholesterol) was calculated using the Friedewald
equation. Serum glycated albumin (GA) was determined
by an enzymatic method using an albumin-specific pro-
teinase, ketoamine oxidase, albumin assay reagents
(LUCICA GA-L, Asahi Kasei Pharma Co., Tokyo, Japan),
and a Hitachi 7699 Pmodule autoanalyzer. The coeffi-
cient of variation (CV) was 1.43%. Serum glycated
hemoglobin (HbA1c) was measured by high-
performance liquid chromatography (HPLC) using a
Variant II Turbo system (Bio-Rad Laboratories,
Hercules, CA). The reference interval for HbA1c was
between 4.0 and 6.0%, while that for GA was between
11.0 and 16.0%. Serum insulin and C-peptide levels were
measured in duplicate using an immunoradiometric
assay (IRMA) method (Beckman Coulter, Fullerton, CA).
The homeostasis model assessment of insulin resistance
Figure 1 Measurement of EAT thickness using cardiovascular
magnetic resonance. Epicardial adipose tissue thickness in the left
atrioventricular groove was measured in the horizontal long-axis
plane in the end-diastolic phase. Maximal EAT thickness was
determined from the myocardial surface to the visceral pericardium.
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(μIU/ml) × fasting glucose (mmol/ml)/22.5.
Cardiac magnetic resonance (CMR) examination
CMR was performed using a 3.0 Tesla magnetic reson-
ance imaging (MRI) unit (Achieva 3.0 T TX, Philips
Medical Systems, The Netherlands) with a 32-channel
receiver coil. Myocardial ischemia was evaluated based
on first-pass myocardial perfusion MR images acquired
during adenosine stress (140 μg/kg/min for 3 minutes)
and at rest with bolus injection of 0.01 mmol/kg of
gadopentetate dimeglumine (MagnevistW, Bayer Scher-
ing Pharma, Berlin, Germany) for each session. After the
perfusion study, whole heart coronary MR angiography
(3-dimensional turbo field echo sequence with navigator
gating) was performed without additional injection of
the contrast medium. Cine MRI was performed with a
balanced steady-state free-precession sequence along the
cardiac short axis and horizontal long axis. Delayed en-
hancement MRI was obtained to assess myocardial via-
bility using a 3-dimensional phase-sensitive inversion
recovery sequence 10 minutes after the rest perfusion
study.
Image analysis and epicardial adipose tissue (EAT)
quantification
CMR images were independently evaluated by two
experienced cardiac radiologists, who were not informed
of the identity or any clinical information about the
patients. After independent evaluation of the images,
final conclusions were made by consensus interpretation.
Abnormal findings on CMR included inducible ischemia,
myocardial infarction, global left ventricular (LV) systolic
dysfunction, and coronary artery stenosis. Inducible is-
chemia was defined as a perfusion deficit induced by ad-
enosine stress on first-pass perfusion images that was
reversed on resting perfusion images with no evidence
of delayed myocardial hyper-enhancement on delayed
enhancement images. Myocardial infarction was defined
as an area with hyper-enhancement consistent with cor-
onary distribution on delayed enhancement MRI. Silent
myocardial ischemia by CMR was defined as an evidence
of inducible ischemia or myocardial infarction. Global
LV systolic dysfunction was defined as LV ejection frac-
tion< 45% measured from cine MRI. Based on coronary
MR angiography, the degree of stenosis was qualitatively
defined as significant, suspected, minimal, or normal.
Focal areas of marked signal loss, signal reduction, or
stenosis of ≥ 50% in the vessel diameter were used as the
criteria for significant stenosis [13,14].
Fat thickness in the left atrioventricular groove was
measured as previously mentioned in studies by other
investigators [15,16]. The measurements were performed
at the end-diastolic phase on the horizontal long-axisplane in cine MRI. Maximal EAT thickness was deter-
mined as measured from the myocardial surface to the
pericardium (perpendicular to the pericardium)
(Figure 1).
Statistical analysis
All statistical analyses were performed with PASW sta-
tistics software (version 18.0; SPSS Inc., Chicago, IL).
Continuous variables with a normal distribution were
expressed as mean ± SD, and discrete variables were
expressed as percentages. The relationship between EAT
thickness and other metabolic parameters was examined
using Pearson’s correlation coefficient (R). Statistical
comparisons between groups according to significant
coronary artery stenosis or silent myocardial ischemia
were performed using the Student’s t test or Mann–
Whitney U test for continuous variables and a χ2 test
for discrete variables. We then used multivariate logistic
regression analysis to assess whether the associations be-
tween EAT thickness and the presence of significant cor-
onary artery stenosis or silent myocardial ischemia were
independent of age, gender, and traditional coronary risk
factors. A P-value< 0.05 was considered significant.
Results
Baseline characteristics of the study participants
Table 1 shows the baseline characteristics of the study
participants. The final population consisted of 100
Table 1 Baseline characteristics of study participants
Total
(n = 100)
Male
(n = 51)
Female
(n = 49)
p value
Age (years) 56 ± 7 55 ± 7 57± 7 0.277
Body-mass index (kg/m2) 25.3 ± 3.2 25.1 ± 3.2 25.6 ± 3.3 0.434
Waist circumference (cm) 86.2 ± 8.0 87.7 ± 7.2 84.6 ± 8.5 0.059
Waist-to-hip ratio 0.91 ± 0.06 0.91 ± 0.05 0.90 ± 0.06 0.303
Systolic blood pressure (mmHg) 130± 13 133 ± 13 127 ± 12 0.013*
Diastolic blood pressure (mmHg) 76 ± 9 79± 9 73± 9 0.002**
DM duration (years) 8.4 ± 6.7 8.5 ± 7.1 8.2 ± 6.3 0.803
Fasting glucose (mmol/L) 6.7 ± 1.7 6.9 ± 1.8 6.6 ± 1.5 0.398
Postprandial glucose (mmol/L) 12.5 ± 3.8 11.8 ± 3.9 13.1 ± 3.7 0.104
HbA1c (%) 7.0 ± 0.9 7.0 ± 1.0 7.1 ± 0.8 0.801
GA (%) 16.7 ± 3.9 16.8 ± 4.3 16.6 ± 3.4 0.782
Total cholesterol (mmol/L) 4.3 ± 0.8 4.2 ± 0.8 4.5 ± 0.8 0.056
LDL cholesterol (mmol/L) 2.5 ± 0.8 2.4 ± 0.6 2.6 ± 0.9 0.115
HDL cholesterol (mmol/L) 1.1 ± 0.2 1.1 ± 0.2 1.2 ± 0.2 0.101
Triglyceride (mmol/L) 1.5 ± 0.7 1.4 ± 0.6 1.6 ± 0.8 0.139
HOMA-IR 4.9 ± 7.8 3.0 ± 0.2 6.6 ± 1.5 0.032*
Cardiovascular magnetic resonance
EAT thickness (mm) 11.9 ± 2.3 12.0 ± 2.1 11.8 ± 2.5 0.738
LV ejection fraction (%) 68 ± 3 67 ± 3 69± 3 0.026*
LV mass (g) 83 ± 21 94 ± 19 71 ± 16 <0.001***
n (%)
Hypertension 45 (45.0) 20 (39.2) 25 (51.0) 0.184
Smoking Hx 18 (18.0) 18 (36.7) 0 (0) <0.001***
Cardiovascular magnetic resonance
Silent myocardial ischemia 14 (14.0) 7 (13.7) 7 (14.3) 0.581
Silent infarction 3 (3.0) 2 (3.9) 1 (2.0) 0.515
Inducible ischemia 13 (13.0) 6 (11.8) 7 (14.3) 0.469
Both 2 (2.0) 1(1.9) 1(2.0) 0.742
Significant stenosis 24 (24.0) 14 (27.5) 10 (20.4) 0.278
Data are presented as mean ± s.d. or n(%). DM diabetes mellitus; HbA1c glycated hemoglobin; GA glycated albumin; LDL low-density lipoprotein; HDL high-density
lipoprotein; HOMA-IR homeostasis model assess of insulin resistance; EAT epicardial adipose tissue; LV left ventricle.
* p<0.05, **p<0.01, ***p<0.001.
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56 ± 7 years). Their mean duration of diabetes was
8.4 ± 6.7 years. The levels of serum HbA1c and GA were
7.0 ± 0.9% and 16.7 ± 3.9%, respectively. The mean body
mass index was 25.3 ± 3.2 kg/m2 (range: 18.7 – 35.6 kg/
m2), and the mean WHR was 0.91 ± 0.06 (range: 0.78 –
1.10). Of these 100 patients, 78 had metabolic syndrome.
A total of 24 patients had significant coronary artery
stenosis defined as stenosis ≥ 50% on coronary MR angi-
ography, and 14 patients had silent myocardial ischemia
on CMR images (1 with silent myocardial infarction, 11
with inducible ischemia, and 2 with both). Ten patients
had both silent myocardial ischemia and significant cor-
onary artery stenosis. The average thickness of the layerof EAT at the left atrioventricular groove was
11.9 ± 2.3 mm (range: 6.8 – 17.9 mm, 12.0 ± 2.1 mm in
males and 11.8 ± 2.5 mm in females). The mean LV ejec-
tion fraction was 68 ± 3%, and all patients had preserved
LV systolic function (range: 56 – 77%). The mean LV
mass was 83 ± 21 g (range: 43 – 165), which was signifi-
cantly greater in males than in females (94 ± 19 g vs.
71 ± 16 g, p<0.001). None of the women was a smoker
in this study.
Subjects with any anatomical (stenosis ≥ 50%) or func-
tional abnormality had a consultation with a specialized
cardiologist. Among 28 patients recommended to
undergo invasive coronary angiography, 20 patients were
submitted for invasive coronary angiography, and 8 were
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ary interventions and 1 coronary artery bypass graft).
Correlation of EAT thickness with metabolic parameters
EAT thickness was positively and independently corre-
lated with metabolic parameters including BMI, waist
circumference, waist-to-hip ratio, systolic blood pres-
sure, postprandial glucose, fasting/postprandial triglycer-
ide, HbA1c level, and HOMA-IR. However, EAT
thickness was not correlated with either LDL-cholesterol
or HDL-cholesterol levels (Table 2).
Association of EAT thickness with significant coronary
artery stenosis or silent myocardial ischemia
We divided the subjects into two different classes: 1)
subjects with or without significant coronary artery sten-
osis, and 2) subjects with or without silent myocardial
ischemia. As shown in Table 3, patients with significant
coronary artery stenosis had significantly higher age,
WHR, systolic blood pressure, total cholesterol, and GA
than those without significant coronary artery stenosis.
EAT thickness was significantly higher in the patients
with stenosis than without stenosis (13.0 ± 2.6 mm vs.
11.5 ± 2.1 mm, p= 0.01). When subjects were divided
based on presence of myocardial ischemia, only BMI
was statistically different between the patients with andTable 2 Metabolic parameters that correlated
independently with EAT thickness based on simple
regression analysis
Simple regression analysis
r P value
Age 0.042 0.677
Body-mass index 0.26 0.009**
Waist circumference 0.297 0.003**
Waist-to-hip ratio 0.404 < 0.001***
Systolic blood pressure 0.223 0.027*
Diastolic blood pressure 0.175 0.085
Fasting glucose 0.105 0.298
Postprandial glucose 0.197 0.049*
Fasting TG 0.256 0.01*
Postprandial TG 0.272 0.009**
Fasting insulin 0.193 0.058
HbA1c 0.324 < 0.001***
GA 0.19 0.065
LDL cholesterol −0.012 0.904
HDL cholesterol −0.115 0.254
HOMA-IR 0.21 0.047*
HbA1c glycated hemoglobin; GA glycated albumin; LDL low-density
lipoprotein; HDL high-density lipoprotein; HOMA-IR homeostasis model assess
of insulin resistance; EAT epicardial adipose tissue; LV left ventricle.
* p<0.05, **p<0.01, ***p<0.001.without silent myocardial ischemia (27.3 ± 3.8 kg/m2vs.
25.0 ± 3.0 kg/m2, p= 0.033) (Table 4A). In a subgroup
analysis based on gender, female patients with myocar-
dial ischemia had a higher EAT thickness than those
without ischemia (14.1 mm (IR 2.5) vs. 11.5 mm (IR 3.4),
p= 0.031). Similar EAT thickness was found between
males with ischemia and without ischemia (11.9 mm (IR
4.2) vs. 12.5 mm (IR 2.9), p= 0.947) (Table 5). Multivari-
ate logistic regression analysis revealed that EAT thick-
ness was an independent indicator of significant
coronary artery stenosis as assessed by coronary MR
angiography, after adjusting for traditional risk factors
(OR 1.403, p= 0.026) (Table 6).
Discussion
Numerous studies have implicated epicardial adipose tis-
sue (EAT) in the development and aggravation of CAD
[1,3,4,17]. However, many questions still remain to be
answered regarding the optimal approach to take for
evaluating the significance of EAT, including its patho-
physiological roles in ischemic heart disease, method for
quantification, and clinical relevance on ischemic heart
disease. Paracrine interaction between EAT and the cor-
onary arteries might underlie the observed pathogenesis
[3]. One possible mechanism might involve the
increased activity of an adipokine associated with EAT.
Adipose tissue secretes various adipokines, including
leptin, adiponectin, resistin, TNF-a, and chemerin. Re-
cent studies have shown that CAD in humans is asso-
ciated with a decreased circulating adiponectin level [18]
or increased expression of chemerin, at both the protein
and mRNA levels, in EAT [19]. In addition, EAT also
shows an association with metabolic syndrome, as
shown by Yorgun et al. [20]. Park et al. [21] recently
reported that EAT was a powerful predictor of metabolic
syndrome and CAD in patients with BMI< 27 kg/m2,
indicating that the measurement of EAT may be more
useful in Asian populations with low BMI than in obese
subjects.
In the present study, we measured the EAT thickness
at the end-diastolic phase on the horizontal long-axis
plane in cine MRI. Nelson et al. [22] validated the use-
fulness of measuring pericardial fat in cine sequences.
Recently, Okayama et al. [23] reported a novel technique
for improved quantification of EAT, especially in the
subjects with elevated T2 signals including pericardial
effusion or myocardial edema. However, we checked the
left ventricular (LV) function, and found that it was pre-
served in all patients. None of our subjects showed peri-
cardial effusion or myocardial edema, indicating that
cine sequences provided optimal measurements of EAT
in our study population.
Numerous studies have focused on the quantification
of EAT, but the best imaging tool and the most optimal
Table 3 A comparison of significant coronary artery stenosis using coronary MR angiography
Significant coronary artery stenosis
(n = 24)
No significant coronary artery stenosis
(n = 76)
p value
Age (years) 60 ± 6 55 ± 7 0.002**
Body-mass index (kg/m2) 26.1 ± 3.6 25.1 ± 3.1 0.240
Waist-to-hip ratio 0.93 ± 0.05 0.90 ± 0.06 0.015*
Systolic blood pressure (mmHg) 137 ± 13 128 ± 12 0.009**
Diastolic blood pressure (mmHg) 76 ± 9 77± 9 0.492
DM duration (years) 9.4 ± 6.6 8.0 ± 6.7 0.261
Smoking history (n, %) 4 (16.7) 14 (18.9) 0.536
Fasting glucose (mmol/L) 7.0 ± 1.9 6.6 ± 1.6 0.617
Postprandial glucose (mmol/L) 13.0 ± 3.1 12.3 ± 4.0 0.26
HbA1c (%) 7.1 ± 0.9 7.0 ± 0.9 0.731
GA (%) 17.8 ± 3.4 16.4 ± 4.0 0.039*
Total cholesterol (mmol/L) 4.7 ± 0.7 4.3 ± 0.8 0.038*
LDL cholesterol (mmol/L) 2.8 ± 0.9 2.4 ± 0.7 0.104
HDL cholesterol (mmol/L) 1.1 ± 0.2 1.1 ± 0.2 0.753
Triglyceride (mmol/L) 1.6 ± 0.7 1.4 ± 0.7 0.212
HOMA-IR 7.0 ± 11.7 4.3 ± 6.2 0.22
Cardiovascular magnetic resonance
EAT thickness (mm) 13.0 ± 2.6 11.5 ± 2.1 0.01**
LV ejection fraction (%) 69 ± 4 68 ± 3 0.488
LV mass (g) 90 ± 24 81 ± 19 0.065
Data are presented as mean ± s.d. or n(%). DM diabetes mellitus; HbA1c glycated hemoglobin; GA glycated albumin; LDL low-density lipoprotein; HDL high-density
lipoprotein; HOMA-IR homeostasis model assess of insulin resistance; EAT epicardial adipose tissue; LV left ventricle.
* p<0.05, **p<0.01, ***p<0.001.
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Many investigators have used echocardiography because
of its easy availability and safety [25], while others have
preferred to use CT scans [26]. However, echocardiog-
raphy has the inherent problem of a limited acoustic
window and variability between operators, while CT
scans result in inevitable, harmful exposure to radiation.
For these reasons, CMR is now gaining popularity as a
promising method for evaluation of CAD, primarily be-
cause of its non-invasive nature and safe characteristics,
especially in diabetic patients who face an increased risk
of contrast-induced nephropathy [27].
Controversy still exists regarding which measurement
of EAT best reflects its metabolic role. Wang et al.
reported that EAT thickness of the left AV groove pro-
vides a more accurate assessment of metabolic risk [15]
and confirmed this with consistent results [16]. Never-
theless, evidence to clarify the clinical relevance of EAT
on ischemic heart disease remains insufficient. We
addressed the discrepancy between CAD and myocardial
ischemia, as well as the relevance of EAT on myocardial
ischemia, by adopting the novel evaluation method of
cardiac magnetic resonance (CMR), which offers func-
tional analysis of myocardial ischemia as well as luminalassessment of the coronary artery. The diagnostic accur-
acy of CMR, is well known, especially with respect to
combined stress perfusion and delayed enhancement in-
farction imaging. Klein et al. [28] and Seeger et al. [29]
recently suggested a possible role for coronary MR angi-
ography in CAD diagnosis.
The present study has four main findings. First, it veri-
fies that EAT thickness measured by CMR is closely
associated with significant CAD evaluated by coronary
MR angiography. Second, it demonstrates that EAT is
not associated with silent myocardial ischemia, as
assessed by combined stress perfusion and delayed en-
hancement infarction in CMR. Third, it shows that
higher EAT thickness is an independent risk factor for
significant CAD, after adjusting for traditional risk fac-
tors such as age, gender, BMI, HbA1c, and blood pres-
sure. Fourth, it shows a gender-based discrepancy in the
association between EAT thickness and myocardial
ischemia.
Clinical relevance of EAT on ischemic heart disease
was indicated from our data, which showed that EAT
measured by CMR was statistically related to insulin
resistance-related metabolic parameters, such as BMI,
waist circumference, waist-to-hip ratio, systolic blood
Table 4 A comparison of silent myocardial ischemia based on CMR findings
Silent myocardial ischemia
(n = 14)
No silent myocardial ischemia
(n = 86)
p value
Age (years) 58 ± 8 56 ± 7 0.278
Body-mass index (kg/m2) 27.3 ± 3.8 25.0 ± 3.0 0.033*
Waist-to-hip ratio 0.94 ± 0.06 0.90 ± 0.05 0.087
Systolic blood pressure (mmHg) 133 ± 9 130 ± 13 0.358
Diastolic blood pressure (mmHg) 74 ± 6 77± 10 0.305
DM duration (years) 10.1 ± 7.5 8.1 ± 6.5 0.396
Smoking history (n, %) 2 (14.3) 16 (19.0) 0.503
Fasting glucose (mmol/L) 6.3 ± 2.0 6.8 ± 1.6 0.072
Postprandial glucose (mmol/L) 13.4 ± 3.6 12.3 ± 3.9 0.200
HbA1c (%) 7.2 ± 0.8 7.0 ± 0.9 0.236
GA (%) 17.9 ± 3.9 16.5 ± 3.9 0.203
Total cholesterol (mmol/L) 4.4 ± 0.9 4.3 ± 0.8 0.941
LDL cholesterol (mmol/L) 2.7 ± 1.3 2.4 ± 0.7 0.602
HDL cholesterol (mmol/L) 1.2 ± 0.2 1.1 ± 0.2 0.453
Triglyceride (mmol/L) 1.3 ± 0.5 1.5 ± 0.7 0.295
HOMA-IR 4.4 ± 3.5 5.0 ± 8.2 0.649
Cardiovascular magnetic resonance
EAT thickness (mm) 12.8 ± 2.1 11.7 ± 2.3 0.111
LV ejection fraction (%) 69 ± 5 68 ± 3 0.353
LV mass (g) 87 ± 28 82 ± 19 0.739
Data are presented as mean ± s.d. or n(%). DM diabetes mellitus; HbA1c glycated hemoglobin; GA glycated albumin; LDL low-density lipoprotein; HDL high-density
lipoprotein; HOMA-IR homeostasis model assess of insulin resistance; EAT epicardial adipose tissue; LV left ventricle.
* p<0.05, **p<0.01, ***p<0.001.
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HbA1c level, and HOMA-IR score. This finding is con-
sistent with data from previous studies that used echo-
cardiography [30] or CT [31] for assessment. Similar to
previous reports, EAT thickness was significantly asso-
ciated with CAD, as evaluated by coronary MR angiog-
raphy. Therefore, EAT might be postulated to have a
major role in the progression of atherosclerosis in the
coronary arteries. However, our results conflict with
those reported by Tamarappoo et al. [32], who showed
that pericardial fat volume measured by CT was signifi-
cantly associated with myocardial ischemia assessed by
single photon emission computed tomography (SPECT).
In the present study, EAT was not associated with silent
myocardial ischemia as assessed by CMR in this study.
These conflicting results may be due to differences in
the study participants, the anatomical site of EAT meas-
urement, and imaging modality. The participants in our
study were asymptomatic type 2 diabetic patients whose
disease was being relatively well controlled (mean
HbA1c = 7.0 ± 0.9%), which could have weakened the as-
sociation between EAT and silent myocardial ischemia.
Interestingly, EAT thickness was significantly asso-
ciated with silent myocardial ischemia in the femalepopulation in our study. Some plausible explanations for
this finding include hormonal influences on adipose tis-
sue metabolism [33] or differential expression of adipo-
nectin and leptin in EAT [34]. Fei et al. [35] showed
age- and sex-matched changes in EAT adipokines in a
rodent model, where aging had a more potent impact on
EAT-derived mediators in female rats than in male rats.
In our study population, the male group, which had a
higher proportion of smokers, showed higher systolic /
diastolic blood pressure and insulin sensitivity than did
the female group. Compared to the male group, females
showed significantly less left ventricular mass (94 ± 19 g
vs. 71 ± 16 g, p<0.001) despite similar EAT thickness
(12.0 ± 2.1 mm vs. 11.8 ± 2.5 mm) (Table 1). In the male
group, no difference was observed in main metabolic
parameters between subjects with and without myocar-
dial ischemia, while in female group, subjects with myo-
cardial ischemia were more obese and had more poorly
controlled glucose when compared to those without is-
chemia. These differences may partly explain the gender
discrepancy; however, no clear reasons were apparent
that would explain why the discrepancy was manifested
only for myocardial ischemia and not for coronary artery
stenosis.
Table 5 Subgroup analysis based on gender
Male (n = 51) Female (n = 49)
Silent myocardial
ischemia
(n = 7)
No silent myocardial
ischemia
(n = 44)
p
value
Silent myocardial
ischemia
(n = 7)
No silent myocardial
ischemia
(n = 7)
p
value
Age (years) 59 55 0.339 58.5 61 0.585
Body-mass index (kg/m2) 26.6 25.3 0.444 28.8 25.0 0.016*
Waist-to-hip ratio 0.90 0.92 0.968 0.93 0.88 0.042*
Systolic blood pressure (mmHg) 136 135 0.870 135 126 0.225
Diastolic blood pressure (mmHg) 81 77 0.203 73 73 0.932
DM duration (years) 6 6 0.725 12 5 0.183
Fasting glucose (mmol/L) 6.4 6.4 0.367 5.5 6.4 0.121
Postprandial glucose (mmol/L) 13.2 11.7 0.698 15.1 12.7 0.198
HbA1c (%) 6.9 6.8 0.989 7.4 6.95 0.069
GA (%) 15.6 15.5 0.942 18.6 15.5 0.096
Total cholesterol (mmol/L) 3.9 4.2 0.511 4.4 4.3 0.51
LDL cholesterol (mmol/L) 2.3 2.3 0.989 2.7 2.5 0.566
HDL cholesterol (mmol/L) 1.1 1.1 0.799 1.2 1.1 0.424
Triglyceride (mmol/L) 1.0 1.3 0.229 1.3 1.4 0.748
HOMA-IR 2.7 2.6 1.000 5.2 3.0 0.586
Cardiovascular magnetic resonance
EAT thickness (mm) 11.9 12.5 0.947 14.1 11.5 0.031*
Data are presented as median. DM diabetes mellitus; HbA1c glycated hemoglobin; GA glycated albumin; LDL low-density lipoprotein; HDL high-density lipoprotein;
HOMA-IR homeostasis model assess of insulin resistance; EAT epicardial adipose tissue.
* p<0.05, ** p≤0.01, *** p≤0.001.
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http://www.cardiab.com/content/11/1/83This study had some limitations. First, this was a
retrospective analysis; therefore, we were unable to ex-
plain the causal relationship between EAT and CAD or
myocardial ischemia. Second, we did not investigate any
inflammation markers. The pathophysiological mechan-
ism of CAD has been suggested to involve the release of
inflammatory signals from epicardial or perivascular adi-
pose tissue, which then promote atherogenesis in the
coronary arteries [3]. Many studies have shown an asso-
ciation between inflammatory markers and EAT [36].
Third, we could not perform a volumetric analysis of
epicardial fat. However, volumetric assessment is time
consuming and requires a skilled observer with sufficient
knowledge of cardiac anatomy [31]. Several recentTable 6 Association between EAT thickness and significant co
regression analysis
Unadjusted
Adjusted for
Age, gender
Age, gender, BMI
Age, gender, BMI, HbA1c, LDL, systotlic blood pressure, smoking history
BMI body mass index; HbA1c glycated hemoglobin; LDL low-density lipoprotein.
* p<0.05, ** p≤0.01, *** p≤0.001.studies have reported a correlation between the EAT
thickness or EAT area and metabolic or cardiovascular
parameters [37]. Lastly, we were unable to confirm the
association between the results of CMR and luminal cor-
onary stenosis because of the absence of angiographic
data for all of the patients in this study.
Conclusions
We demonstrated that increased EAT thickness assessed
by CMR was an independent risk factor for significant
coronary artery stenosis in asymptomatic type 2 diabetes
patients. However, this thickness was not associated with
silent myocardial ischemia. In a subgroup analysis, EAT
thickness was associated with silent myocardial ischemiaronary artery stenosis based on multivariate logistic
OR 95% CI for OR Pvalue for EAT effect
1.340 1.073 - 1.674 0.01**
1.334 1.062 - 1.677 0.013*
1.262 0.993 - 1.603 0.057
1.403 1.042 - 1.890 0.026*
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http://www.cardiab.com/content/11/1/83in females but not in males. Further studies are war-
ranted to discover why EAT is associated with coronary
stenosis but not with myocardial ischemia, in asymp-
tomatic type 2 diabetic patients. In addition, the possible
gender-based differences in the role of EAT should be
further evaluated.
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